Related Experiment Video
Updated: May 8, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia
Mayrim L Pérez1, Sarah Culver, Jennifer L Owen
1Departments of aSmall Animal Clinical Sciences bPhysiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida cDepartment of Molecular Biomedical Sciences dDepartment of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, College of Veterinary Medicine, North Carolina State University, Raleigh eCancer Genetics Program, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
Abstract:
Treatment of chronic monocytic leukemia (CMoL) in dogs has traditionally consisted of hydroxyurea. The use of tyrosine kinase inhibitors has been proposed as a treatment option for dogs with CMoL but has never been reported. We report a case of CMoL in a young dog that achieved clinical remission with treatment with the tyrosine kinase inhibitor toceranib and prednisone.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
